The Priority Review

Tag

Colon cancer

1 story

Stories

  1. Approvals

    FDA approves atezolizumab plus chemotherapy for Stage III dMMR colon cancer

    The FDA approved atezolizumab with a fluoropyrimidine and oxaliplatin for Stage III mismatch repair deficient colon cancer, citing a disease-free survival hazard ratio of 0.50 in 711 adults and one pediatric patient. The approval covers adults and pediatric patients two years of age and older after complete resection.